Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine + Docetaxel vs Capecitabine + Docetaxel in Metastatic Breast Cancer
NCT00191152Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Feb 2002
- Primary completion
- Nov 2008
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 3, randomised, open-label trial of gemcitabine in breast cancer (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Time to Disease Progression (Initial Treatment) up to 82 months. Started Feb 2002; status: completed.
02
Drugs
gemcitabine
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00191152.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00191152.